PT1768677E - Ácidos nucleicos para o tratamento de patologias relacionadas com hmgb1 - Google Patents

Ácidos nucleicos para o tratamento de patologias relacionadas com hmgb1 Download PDF

Info

Publication number
PT1768677E
PT1768677E PT05773148T PT05773148T PT1768677E PT 1768677 E PT1768677 E PT 1768677E PT 05773148 T PT05773148 T PT 05773148T PT 05773148 T PT05773148 T PT 05773148T PT 1768677 E PT1768677 E PT 1768677E
Authority
PT
Portugal
Prior art keywords
treatment
hmgb1
nucleic acids
related pathologies
nucleic acid
Prior art date
Application number
PT05773148T
Other languages
English (en)
Portuguese (pt)
Inventor
Marco E Bianchi
Domenico G Barone
Enrico M Bucci
Silvano Fumero
Margherita Valente
Roberto Sapio
Domenica Musumeci
Original Assignee
Creabilis Therapeutics Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35106975&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1768677(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Creabilis Therapeutics Spa filed Critical Creabilis Therapeutics Spa
Publication of PT1768677E publication Critical patent/PT1768677E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3181—Peptide nucleic acid, PNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/52—Physical structure branched

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT05773148T 2004-07-02 2005-07-04 Ácidos nucleicos para o tratamento de patologias relacionadas com hmgb1 PT1768677E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58467804P 2004-07-02 2004-07-02
US64658605P 2005-01-26 2005-01-26

Publications (1)

Publication Number Publication Date
PT1768677E true PT1768677E (pt) 2008-10-06

Family

ID=35106975

Family Applications (1)

Application Number Title Priority Date Filing Date
PT05773148T PT1768677E (pt) 2004-07-02 2005-07-04 Ácidos nucleicos para o tratamento de patologias relacionadas com hmgb1

Country Status (14)

Country Link
US (1) US20080305073A1 (enExample)
EP (1) EP1768677B1 (enExample)
JP (1) JP2008504335A (enExample)
AT (1) ATE399014T1 (enExample)
AU (1) AU2005259381A1 (enExample)
BR (1) BRPI0512944A (enExample)
CA (1) CA2572519A1 (enExample)
DE (1) DE602005007746D1 (enExample)
DK (1) DK1768677T3 (enExample)
ES (1) ES2306195T3 (enExample)
IL (1) IL179828A0 (enExample)
PL (1) PL1768677T3 (enExample)
PT (1) PT1768677E (enExample)
WO (1) WO2006002971A2 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101323411B1 (ko) 2004-08-03 2013-10-30 트랜스테크 파르마, 인크. Ｒａｇｅ 융합 단백질 및 이의 사용 방법
US20100172909A1 (en) * 2005-10-24 2010-07-08 Masahiro Nishibori Cerebral edema suppressant
EP1989227A2 (en) * 2006-02-09 2008-11-12 Transtech Pharma, Inc. Rage fusion proteins and methods of use
JP3882090B1 (ja) * 2006-05-19 2007-02-14 国立大学法人 岡山大学 脳血管攣縮抑制剤
KR20090087483A (ko) * 2006-11-17 2009-08-17 클리니컬 진 네트웍스 아베 유전자 ｇｙｐｃ, ａｇｐａｔ3, ａｇｌ, ｐｖｒｌ2, ｈｍｇｂ3, ｈｓｄｌ2 및/또는 ｌｄｂ2를 포함하는 스크리닝 및 치료방법
CN101589309A (zh) * 2006-11-17 2009-11-25 临床基因网络公司 涉及基因gypc、agpat3、agl、pvrl2、hmgb3、hsdl2和/或ldb2的筛选和治疗方法
WO2009140676A2 (en) * 2008-05-16 2009-11-19 Immune Disease Institute, Inc. Compositions and methods for inhibition of retroviruses
US8710021B2 (en) 2008-06-11 2014-04-29 Bionucleon S.R.L. Inhibition of HRP-3 using modified oligonucleotides
BRPI0916349A2 (pt) 2008-09-11 2019-09-24 Pasteur Institut monitoramento e inibição da infecção pelo vírus da imunodeficiência humana através da modulação do desencadeamento dependete de hmgb1 da replicação e persistência do hiv-1
US20120165244A1 (en) * 2008-10-30 2012-06-28 Hua-Lin Wu Methods for binding lewis y antigen
KR101431165B1 (ko) 2008-12-22 2014-08-18 크레아빌리스 에스.에이. 인돌로카르바졸 화합물의 중합체 컨쥬케이트의 합성
RU2011142230A (ru) 2009-04-20 2013-05-27 Пфайзер Инк. Контроль гликозилирования белка и композиции и способы, касающиеся этого
GB0911569D0 (en) * 2009-07-03 2009-08-12 Ulive Entpr Ltd Method for the detection of organ or tissue injury
JP5467313B2 (ja) * 2009-09-28 2014-04-09 国立大学法人 岡山大学 アテローム動脈硬化抑制剤
US8975019B2 (en) * 2009-10-19 2015-03-10 University Of Massachusetts Deducing exon connectivity by RNA-templated DNA ligation/sequencing
CN103096899B (zh) 2010-09-17 2015-01-28 独立行政法人科学技术振兴机构 由 hmgb 蛋白介导的免疫应答激活的抑制剂及筛选方法
WO2013116590A1 (en) * 2012-02-01 2013-08-08 George Miller Inhibition of pattern recognition receptors in pancreatic cancer treatment using tlr inhibitors
JP6624542B2 (ja) * 2015-02-05 2019-12-25 国立大学法人広島大学 ヒトｈｍｇｂ１結合剤およびヒトｈｍｇｂ１除去装置
WO2018175301A1 (en) 2017-03-20 2018-09-27 Sienna Biopharmaceuticals, Inc. Polymer conjugate of montesanib with reduced exposure
WO2018175315A1 (en) 2017-03-20 2018-09-27 Sienna Biopharmaceuticals, Inc. Polymer conjugates of staurosporine derivatives having reduced exposure
WO2018175302A1 (en) 2017-03-20 2018-09-27 Sienna Biopharmaceuticals, Inc. Polymer conjugates targeting c-src with reduced exposure
EP3600440A1 (en) 2017-03-20 2020-02-05 Sienna Biopharmaceuticals, Inc. Reduced exposure conjugates modulating therapeutic targets
EP3621657A1 (en) 2017-05-10 2020-03-18 Sienna Biopharmaceuticals, Inc. Uses of polymer conjugates of indolocarbazole compounds with reduced exposure
CN111304202B (zh) * 2020-02-26 2023-03-28 西安交通大学 一种用于识别且增强hmgb1生物学活性的核酸适配子及其应用
CN114957440A (zh) * 2022-05-26 2022-08-30 江苏大学 一种重组HMGB1 A Box蛋白及其获取方法与应用
US20250262230A1 (en) * 2022-06-23 2025-08-21 The Regents Of The University Of California HMGB1 Inhibitors for Treatment of APOE4-related Tauopathies including Alzheimer’s Disease
CN114807150B (zh) * 2022-06-28 2022-10-14 中国科学院基础医学与肿瘤研究所(筹) 靶向和拮抗hmgb1分子的核酸适体
JP2025525583A (ja) 2022-07-19 2025-08-05 ランパート バイオサイエンス インコーポレイテッド 非免疫原性環状非ウイルス性ｄｎａベクター
CN115774004B (zh) * 2022-08-19 2024-07-05 四川大学华西医院 二氧化锆@量子点复合微球在制备检测hmgb1的荧光探针中的用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5442194A (en) * 1992-10-14 1994-05-09 University Research Corporation Method for selecting nucleic acids on the basis of structure
ITMI20010562A1 (it) * 2001-03-16 2002-09-16 Marco E Bianchi Inibitori o antagonisti della proteina hmg1 per il trattamento di disordini vascolari
NZ540067A (en) * 2002-11-20 2007-05-31 Critical Therapeutics Inc A purified preparation of antibodies that specifically bind to a high mobility group box protein (HMGB) B box but do not specifically to non-B box epitopes of HMGB

Also Published As

Publication number Publication date
PL1768677T3 (pl) 2009-01-30
ATE399014T1 (de) 2008-07-15
CA2572519A1 (en) 2006-01-12
JP2008504335A (ja) 2008-02-14
BRPI0512944A (pt) 2008-04-15
WO2006002971A3 (en) 2006-04-20
AU2005259381A1 (en) 2006-01-12
WO2006002971A2 (en) 2006-01-12
DE602005007746D1 (de) 2008-08-07
US20080305073A1 (en) 2008-12-11
EP1768677B1 (en) 2008-06-25
EP1768677A2 (en) 2007-04-04
DK1768677T3 (da) 2008-10-20
ES2306195T3 (es) 2008-11-01
IL179828A0 (en) 2008-03-20

Similar Documents

Publication Publication Date Title
PL1768677T3 (pl) Kwasy nukleinowe do leczenia patologii związanych z HMGB-1
BR112012017348A2 (pt) "análogo de peptídeo de oxintomodulina"
MX2007009807A (es) Agentes terapeuticos de aptameros utiles en el tratamiento de trastornos relacionados con el complemento.
DK2066684T3 (da) 5´-Modificerede bicycliske nukleinsyreanaloge
DK1999160T3 (da) Acryleret hyaluronsyre
WO2009114475A3 (en) Compositions comprising human pcsk9 and apolipoprotein b sirna and methods of use
WO2008101857A3 (en) Coryneform bacteria with formate-thf-synthetase and/or glycine cleavage activity
EA200600735A1 (ru) Нуклеиновые кислоты, специфично связывающие биоактивный грелин
DE602005017027D1 (de) Verfahren zur enzymatischen herstellung von (s)-3-cyano-5-methylhexansäure
ATE476414T1 (de) Biphenyloxyessigsäurederivate zur behandlung von atemwegserkrankungen
DK2135949T3 (da) MCP-1-bindende nukleinsyrer
WO2008135180A3 (en) Pet food and a process for its manufacture
WO2010003420A3 (en) Treatment of psoriasis and related diseases by mirna modulation
ATE447551T1 (de) Biphenyloxyessigsäure - derivate zur behandlung von atemwegserkränkungen
ATE472998T1 (de) Kationische liposomale zubereitungen zur behandlung von rheumatoider arthritis
WO2008016906A3 (en) 3'-phosphate-labeled nucleotide analogs and their use for sequencing a nucleic acid
EA200702336A1 (ru) ПРИМЕНЕНИЕ 24-норУДХК
WO2006132739A3 (en) Novel chemical compounds
DE602005013650D1 (de) Proteinhydrolysat zur behandlung von müdigkeit
EP1966228A4 (en) PURIFICATION METHOD FOR CHENODESOXYCHOLIC ACID
UA93658C2 (en) Cell surface glycoprotein
GB0423126D0 (en) Protein
EP1757685A4 (en) MODIFIED ETHYLENEDIAMIN N, N'-DIBERNIC ACID: ETHYLENEDIAMINE LYASE
DE602007001037D1 (de) Verfahren zur Herstellung von Acrylsäure
WO2006127458A3 (en) Novel chemical compounds